Veracyte (VCYT) Trading Volume Steady Despite Market Uncertainty
April 9, 2023
Trending News ☀️
Veracyte ($NASDAQ:VCYT) Inc. (VCYT) is an innovator in molecular diagnostics and personalized medicine that provides diagnostic solutions to transform patient care. The company has made tremendous strides in the field of precision medicine, providing information to physicians to help diagnose and guide treatment decisions for patients with cancer and other difficult-to-diagnose diseases. Recently, despite the uncertain stock market, the trading volume of Veracyte Inc. (VCYT) has remained consistent. This consistency is a reflection of the confidence investors have in the company’s performance and prospects.
The company’s commitment to developing and offering innovative diagnostic products to improve health outcomes has made it a top pick among investors. Its products are improving outcomes for patients, making it a top choice for many investors.
Price History
On Wednesday, the stock opened at $21.0 and closed at $21.5, representing a 4.3% increase from the prior closing price of $20.6. This jump marks a sign of continued investor confidence in VERACYTE amid the current market volatility. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Veracyte. More…
| Total Revenues | Net Income | Net Margin |
| 296.54 | -36.56 | -12.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Veracyte. More…
| Operations | Investing | Financing |
| 7.54 | -29.39 | 3.49 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Veracyte. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.16k | 81.22 | 14.94 |
Key Ratios Snapshot
Some of the financial key ratios for Veracyte are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 35.1% | – | -12.2% |
| FCF Margin | ROE | ROA |
| -0.3% | -2.1% | -2.0% |
Analysis
GoodWhale has conducted an analysis of VERACYTE‘s fundamentals and concluded that it is classified as a ‘cheetah’ type of company. This means that VERACYTE has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for quick returns or are more risk tolerant may be interested in this type of company. An intermediate health score of 4/10, taking into account its cashflows and debt, suggests that VERACYTE is likely to sustain future operations in times of crisis. Overall, VERACYTE is strong in asset and growth, but weak in dividend and profitability. More…
Peers
The company’s competitors include Exact Sciences Corp, Invitae Corp, and NanoString Technologies Inc.
– Exact Sciences Corp ($NASDAQ:EXAS)
Exact Sciences Corp has a market cap of 7.56B as of 2022. The company’s ROE for the same year is -14.13%.
Exact Sciences Corp is a biotechnology company that focuses on the development of cancer detection tests. The company’s flagship product is Cologuard, a stool-based DNA test that can detect the presence of colorectal cancer.
– Invitae Corp ($NYSE:NVTA)
Invitae Corp is a biotechnology company that uses genetic information to help healthcare providers diagnose, treat and prevent disease. The company has a market cap of 689.82M as of 2022 and a Return on Equity of -120.15%.
– NanoString Technologies Inc ($NASDAQ:NSTG)
NanoString Technologies Inc is a molecular diagnostics company that develops and sells proprietary technologies and instruments for digital molecular profiling. The company has a market capitalization of 313.93 million as of 2022 and a return on equity of -87.4%. NanoString’s technology is based on a unique digital detection platform that can measure the expression of hundreds of genes simultaneously with high accuracy and precision. The company’s products are used in a variety of applications, including gene expression profiling, copy number variation analysis, single-nucleotide polymorphism genotyping, and mRNA quantification. NanoString’s products are sold to a diverse customer base, including academic research institutions, government laboratories, pharmaceutical and biotechnology companies, and diagnostic laboratories.
Summary
Veracyte Inc. (VCYT) has been seeing steady trading volumes over the recent period. Its stock price has also been increasing, indicating that investors are feeling positive about the company’s prospects and are making investments in it. Analysts believe that the company’s focus on developing innovative diagnostic tests that provide physicians and their patients with more information when making healthcare decisions has been successful in generating interest from investors.
Furthermore, its strong financial performance, including increasing revenue and shrinking losses in recent quarters, has been a major factor in driving investor confidence. With this positive momentum, analysts expect that the future holds even greater potential for Veracyte as it continues to improve its offerings and expand into new markets.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
